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ABSTRACT
Introduction: Delayed graft function due to
ischaemia-reperfusion injury is a frequent
complication in deceased donor renal transplantation.
Experimental evidence indicates that remote
ischaemic conditioning (RIC) provides systemic
protection against ischaemia-reperfusion injury in
various tissues.
Methods and analysis: ‘Remote ischaemic
conditioning in renal transplantation—effect on
immediate and extended kidney graft function’ (the
CONTEXT study) is an investigator initiated,
multicentre, randomised controlled trial investigating
whether RIC of the leg of the recipient improves short
and long-term graft function following deceased donor
kidney transplantation. The study will include 200
kidney transplant recipients of organ donation after
brain death and 20 kidney transplant recipients of
organ donation after circulatory death. Participants are
randomised in a 1:1 design to RIC or sham-RIC
(control). RIC consists of four cycles of 5 min
occlusion of the thigh by a tourniquet inflated to
250 mm Hg, separated by 5 min of deflation. Primary
end point is the time to a 50% reduction from the
baseline plasma creatinine, estimated from the changes
of plasma creatinine values 30 days post-transplant or
30 days after the last performed dialysis post-
transplant. Secondary end points are: need of dialysis
post-transplant, measured and estimated-glomerular
filtration rate (GFR) at 3 and 12 months after
transplantation, patient and renal graft survival, number
of rejection episodes in the first year, and changes in
biomarkers of acute kidney injury and inflammation in
plasma, urine and graft tissue.
Ethics and dissemination: The study is approved
by the local ethical committees and national data
security agencies. Results are expected to be published
in 2016.
Trial registration number: NCT01395719.
INTRODUCTION
Delayed graft function (DGF) following
deceased donor kidney transplantation may
lead to need of dialysis, increased incidence
of post-transplant complications and pro-
longed hospitalisation.1–3 In transplantation
with kidneys from brain death donors (DBD),
DGF is associated with an increased risk of
acute rejection episodes, and impaired graft
function and survival.1 2 4–6 DGF is closely
related to ischaemia-reperfusion injury (IRI)
and complicates 20–45% of transplantations
from DBD,5 and 50–75% of transplantations
with kidneys from circulatory death donors
(DCD).7–9 The incidence of DGF and also
primary non-function might increase with
higher acceptance of extended criteria
donors and thus lower organ quality, necessi-
tated by the persisting organ shortage.
Remote ischaemic conditioning (RIC) has
been shown to protect against IRI in various
tissues.10 11 In the heart, this was shown in
animal studies of myocardial injury,12 13 as
well as in clinical trials after acute myocardial
infarction (AMI)14 15 and following heart
surgery in children.16 Lately, RIC has been
shown to affect long-term clinical outcomes
positively, including a reduction in all-cause
mortality after AMI and coronary artery
bypass surgery.17 18 Clinical trials have also
shown that RIC protects against acute kidney
injury (AKI), for example, after cardiac
surgery19 or interrupted renal blood supply
during elective aortic surgery;20 however, this
ﬁnding has not been conﬁrmed in all
studies.21–23 It has been suggested that RIC
may protect against DGF after kidney
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transplantation.24–26 In a porcine DBD transplantation
model, we have shown that RIC on the recipient animal
was associated with higher glomerular ﬁltration rate
(GFR) and plasma perfusion of the transplanted kidney
within the ﬁrst 10 h of reperfusion.27 So far, two clinical
trials investigating the effect of RIC in kidney transplant-
ation have been published: a small trial (published as a
letter to editor), using RIC in living donor kidney trans-
plantation, studied three groups with 20 kidney-
transplanted patients in each, exposed to either donor
RIC, recipient RIC or nothing (control group).28 No
effect of RIC was observed on the incidence of DGF,
plasma creatinine (p-cr) levels, urinary output, hospital-
isation days and costs or various biomarkers in plasma
and urine. The negative ﬁnding, however, was limited by
the low sample size and the known low frequency of DGF
from live donation. Another small trial applying RIC to
DCD recipients (n=48), showed that RIC was associated
with an increase in early estimated-GFR (eGFR) and a
decrease in urine concentration of the renal injury
marker neutrophil gelatinase-associated lipocalin
(NGAL).29
The CONTEXT study investigates the effect of RIC in
recipients of kidneys from deceased donors, including
mainly DBD, as well as DCD, in a block randomised
design. To our knowledge, three other randomised clin-
ical trials are presently investigating the effects of differ-
ent RIC strategies in kidney transplantation (the
REPAIR trial (UK and the Netherlands),30 the RIPNOD
study (US)31 and ‘Remote Post-Conditioning (RPC) in
renal transplantation’ (UK)32). The protocols of these
studies differ in several ways from the CONTEXT study,
both with respect to RIC procedure and the patient
study groups.
In addition to studying the effect of RIC on renal
function and clinical outcome, the newest concepts and
technologies will be used to identify various ischaemic,
inﬂammatory and immunological biomarkers and med-
iators in renal tissue, urine and blood expected to be
associated with ischaemia-reperfusion injury and RIC.
Obtained knowledge in this ﬁeld will potentially have
high impact in prevention of AKI in transplantation and
other clinical settings.
METHODS AND ANALYSIS
Study type
An investigator initiated multicentre, randomised, con-
trolled and prospective clinical trial. The study is
blinded to the patient, surgeons and treating physicians.
Study population
Patients above 18 years of age receiving a DBD (n=200)
or DCD (n=20) renal transplant at Aarhus University
Hospital, Aarhus, Denmark; Sahlgrenska University
Hospital, Gothenburg, Sweden; University Medical
Center Groningen, Groningen, and Erasmus MC,
University Medical Center, Rotterdam, the Netherlands.
Kidney transplantation from DCD is carried out only in
the latter two centres.
The Dutch centres will be starting inclusion after the
Scandinavian centres and thus, only a minor group of
DCD recipients will be included in the present study,
which depending on the results, can be expanded.
Donor and recipient selection follow the regional
allocation programmes, Scandiatransplant (Aarhus
and Gothenburg) and Eurotransplant (Groningen and
Rotterdam). Final recipient selection in Aarhus and
Gothenburg is based on local guidelines regarding
immunological match and speciﬁed donor/recipient
characteristics independent of the CONTEXT protocol.
See table 1 for study inclusion and exclusion criteria.
Treatment before and during the operation is speciﬁed
below. Concomitant care and interventions during the
study follow-up period are carried out according to
local standards. The patients cannot participate in
other randomised intervention trials during the
follow-up period.
Randomisation
Patients are informed and enrolled into the study by the
surgeon or physician on duty. Randomisation, interven-
tion and handling of study samples is carried out by a
trained study crew member attending the operation who
is either a medical student, a laboratory technician or
the local, principal investigator (who is not involved in
the patient care). Patients are randomised in a 1:1
fashion to either RIC or sham-RIC (control group) strati-
ﬁed by centre and donor type, using an online block
randomisation programme. When both recipients of the
kidneys from the same donor are included in the study,
they are randomised within kidney pairs (ﬁgure 1) and
stratiﬁed by operation sequence, in order to distribute
cold ischaemia time evenly.
Figure 2 shows the sampling and study timeline.
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
▸ Deceased donor kidney
transplantation
candidate
▸ AV-fistula in the leg of
planned RIC (opposite to
the side of graft
implantation)
▸ Aged 18 years or older ▸ Increased risk of
complications from RIC
due to pre-existing lower
limb ischaemia (as
determined by the
investigator)
▸ Informed consent ▸ Unable to deliver informed
consent
▸ Double kidney transplant
recipient
AV, arteriovenous; RIC, remote ischaemic conditioning.
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RIC or sham
In the operation theatre, prior to the start of surgery, an
appropriately sized tourniquet is placed on the thigh of
all patients opposite to the side of planned graft
implantation. The RIC/sham procedure is initiated
approximately 40 min prior to the expected time of
graft reperfusion, usually shortly after the skin incision.
If the patient is randomised to RIC, the blood supply to
the lower limb is occluded by inﬂation of the tourniquet
to 250 mm Hg in four cycles of 5 min, separated by
5 min of deﬂation to allow free blood ﬂow. The tourni-
quet remains deﬂated in the control group, but the
activity of the attending staff is as in the intervention
group. The randomisation is blinded to the surgeons
and anaesthesiologist. RIC is terminated just prior to
graft reperfusion even if the four cycles are not fully
completed.
Anaesthesia and transplantation procedures
Anaesthesia is induced with propofol and fentanyl/remi-
fentanil. To facilitate tracheal intubation and to optimise
ventilation and surgical conditions, cisatracurium is used
as a muscle relaxant. Anaesthesia is maintained with
sevoﬂurane and analgesia with fentanyl or remifentanil
according to local protocol. Volatile anaesthetic agents
were chosen because of their possible amplifying effect
on RIC.33–35 The surgical procedure follows local stan-
dards. Fluid replacement therapy during the procedure
is based on crystalloids, either normal saline or Ringers
Lactate and human albumin. No synthetic colloids are
used. Hypotension during surgery is managed at the dis-
cretion of the attending anaesthesiologist. Before reper-
fusion, 200–350 mL Mannitol 15% is given according to
local protocol.
Immunosuppression
The immunosuppressive regimen is based on induction
with intravenous basiliximab and methylprednisolone or
corresponding oral doses of prednisolone, followed by oral
tacrolimus, mycophenolate mofetil and prednisolone
(starting at 20 mg/day and slowly tapered to 5 mg/day).
Primary end point
The primary end point is the estimated time to a 50%
decrease in plasma-creatinine (p-cr). Baseline p-cr is
measured approximately 1 h prior to the graft reperfu-
sion. P-cr is then measured at least twice daily day 1–4,
once daily day 5–7 and two times weekly until 30 days
after transplantation. For patients requiring temporary
dialysis post-transplant, p-cr is measured continuously
until 30 days after the last dialysis. All p-cr values will be
noted with date and time of the sample, and the time
(hours) since reperfusion will be calculated. The
observed, time dependent changes in p-cr are modulated
for each patient by an exponential, logistic or a linear
model; by using this model, the p-cr at reperfusion (time
0) and the time to a 50% decrease of this value is esti-
mated. This primary end point will allow the inclusion in
the analysis of all patients who acquire kidney graft func-
tion with a GFR greater than about 20 mL/min, includ-
ing patients requiring initial, temporary dialysis.
Secondary end points
Need of dialysis post-transplant. GFR measured by
51Cr-EDTA or iodothalamate plasma clearance at day 5,
and 3 and 12 months post-transplant. Number of acute
rejection episodes the ﬁrst year post-transplant. Patient
and renal graft survival. Absolute levels of and changes
in expression of renal tissue markers at day 6 post-
transplant compared to time zero. Metabolomics and
proteomics analyses on paired kidney biopsies on day 6.
Plasma concentration and urinary excretion of markers
and mediators of renal injury and RIC based on various
assays, including ELISA and expression array studies.
Among others, the AKI marker NGAL36 37 will be mea-
sured in urine and plasma, as well as the markers liver
Figure 1 Randomisation algorithm (RIC or sham-RIC, 1:1)
by the online block randomisation programme, stratified by
centre and donor type. When both recipients of a kidney pair
are included, randomisation is also stratified by operation
order. RIC, remote ischaemic conditioning
Figure 2 Timing of intervention (± remote ischaemic
conditioning), samples, measurements and follow- up; mGFR,
measured glomerular filtration rate.
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fatty acid-binding protein,38 cystatin C36 and YKL4039
(only in urine). Further analyses are still to be decided.
Statistics
The primary analyses of the outcome parameters will be
based on the results of recipients of both donor groups;
secondary analyses will investigate the results divided
into donor subgroups.
Outcomes will be presented as means with SDs and
groups will be compared using Student t test if data are
normally distributed, and if not compared by the
Wilcoxon two-sample rank sum test. Binary outcomes
will be analysed using χ2 test or Fisher’s exact test.
Repeated measurements will be analysed using a
repeated measurement analysis of variance. A linear
mixed effects model will be applied with treatment and
time as ﬁxed effects, and with recipient and donor as
random effects.
The p value <0.05 will be considered statistically
signiﬁcant.
The sample size was determined based on estimates
from a pilot study including 62 kidneys from 54 DBD.
The geometric mean time to reach 50% of the initial
p-cr level was 57.04 h and the geometric SD was 2.44 h
within donors and 2.33 h between donors. The sample
size was calculated under the assumption that all new
donors would contribute two kidneys each, which would
be randomised to either RIC or sham-RIC (control).
The number of donors should be large enough to deter-
mine a statistical signiﬁcant 30% decrease in the time to
reach a 50% p-cr reduction in the RIC group compared
to the sham-RIC group. The test for no treatment effect
was based on the likelihood ratio test statistic from a
linear mixed effects analysis, with treatment as ﬁxed
effect and donor as a random effect. The signiﬁcance
level was set to 0.05 and the power to 0.80. The result of
the sample size calculation was that a total of 100 donors
are needed, thus 200 recipients. With the inclusion of
the Dutch centres we have decided to include 20 recipi-
ents extra, as it is anticipated that not all donors will
contribute two kidneys. The primary analysis will be on
all recipients, with subanalyses on DBD and DCD.
Study group
The study group is composed of the trial sponsor in
Aarhus (BJ, HB and NVK, the latter principal investiga-
tor) and local investigator in Gothenburg MO, local
investigator in Groningen GJNM and local investigator
in Rotterdam FJMFD. Each investigator is locally in
charge of the execution of the study, and gathering of
samples and data. Trial sponsor is in charge of data
entry, storage, statistical analyses and writing. Legal study
agreements are made between trial sponsor and each
additional study site regarding performance of the study,
timelines and recruitment, reporting, data management,
conﬁdentiality and intellectual property, publication,
liability and indemniﬁcation, termination, law and
venue.
ETHICS AND DISSEMINATION
Ethical and safety considerations
The study protocol, including consent form and partici-
pant information, is approved by the national agencies
in Denmark, Sweden and the Netherlands, including
the local ethical committees (Denmark: 31894
November 2011, Netherlands 2013/141) and the Data
protection agencies (Denmark: J.nr. 2011-41-6477). All
minor and major amendments to the protocol need
approval by the ethical committees. A data monitoring
committee was not required.
The tourniquet used is designed to create bloodless
operation ﬁelds and is often used in orthopaedic opera-
tions. With prolonged usage (>1 h), skin damages can
occur if the skin is folded under a badly applied tourni-
quet. This is not likely to occur using short, repeated RIC
interrupted by free ﬂow of blood, as described. To our
knowledge, no adverse events have been reported by other
clinical trials applying RIC on a limb with a tourniquet.
A serious adverse event possibly related to the ischaemic
insult of the leg is believed to have happened within the
ﬁrst week after the operation. According to the seriousness
of the event, the intervention of the patient can be
unblinded after internal discussion in the study group.
The anaesthetised patient will experience no
discomfort.
The study is conducted in accordance with the ethical
principles of the Declaration of Helsinki and the
Declaration of Istanbul. Authorship will be decided as
described in the legal study agreements between trial
sponsor and additional study sites, and according to the
Vancouver guidelines.
Dissemination plan
Results will be presented at national and international
meetings and in the media, and published in inter-
national peer-reviewed medical journals. First results are
expected in 2016.
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